With NHS waiting lists at all-time highs, this FTSE 250 stock has an enviable growth path.
Spire Healthcare, a leading independent hospital group in the UK, announced robust results for the first half of 2023.
The company’s strong performance, with a 13.1% increase in revenue driven by growing demand, reflects a broader trend. More individuals are turning to private healthcare, partly due to long NHS wait times exacerbated by the pandemic.
Spire says its success is a testament to its strategic adaptability and commitment to quality care.
Not optimistic enough?
Spire has a sky-high price-to-earnings (P/E) ratio of 42.6, suggesting investors are very optimistic about the company’s potential.
At the same time, a discounted cash flow model shows the stock is undervalued by 61%.
Typically, a high P/E ratio, such as Spire’s, would be a red flag, signalling market exuberance and a possible bubble waiting to burst.
However, the substantial undervaluation suggested by the discounted cash flow analysis implies the opposite.
In this rare case, investors might actually not be optimistic enough, despite the eye-watering P/E ratio.
Indeed, analysts forecast the company can grow its earnings at a whopping 36% a year. If Spire really can live up to this expectation, its stock price should soar. That’s because right now the market is pricing in a much gloomier scenario, in defiance of analysts’ cheer.
Inelastic demand
In 2023, inflation and the cost-of-living crisis loomed large, yet Spire appeared somewhat insulated. Research suggests that their typical private patient prioritises healthcare spending, potentially safeguarding the company from the worst financial pressures faced by other sectors.
Political risks abound
Of course, Spire has its challenges. The risks of investing in the UK’s private healthcare providers are obvious. Just five years ago, the Labour Party manifesto proposed an end to private providers in the NHS. If Jeremy Corbyn had won, that would have annihilated around one-quarter of Spire Healthcare’s revenue.
Another scenario worth considering is one in which the NHS’s waiting lists are dramatically reduced due to a massive funding injection. In that case, it would no longer seem so appealing to pay thousands of pounds out of pocket to jump the queue. Spire’s biggest rival is any business’ worst nightmare: a state-backed organisation handing out the same service with a price tag of zero.
But that’s only one scenario. Personally, I am not optimistic about the NHS’s ability to cope. The ongoing pressures on the NHS, exacerbated by an ageing population, seem likely to continue diverting more individuals and employers towards private healthcare options. Spire could also benefit from the shortage of skilled labourers in certain sectors in the UK if private health insurance increasingly becomes used as a way to retain talented workers.
I plan to open a small position in Spire when I next have spare cash to invest.
The post Potentially 61% undervalued, is this FTSE 250 stock an unmissable buy? appeared first on The Motley Fool UK.
Should you buy Spire Healthcare now?
Don’t make any big decisions yet.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.
And he believes they could bring spectacular returns over the next decade.
Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows…
When such enormous changes hit a big industry, informed investors can potentially get rich.
So, with his new report, Mark’s aiming to put more investors in this enviable position.
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
3 reasons I’m avoiding Rolls-Royce shares
One number I think investors need to know before considering buying Tesco shares
How I’d aim to turn £500 a month into a stunning passive income of almost £350k a year
Could the UK stock market roar back in 2024?
2 ‘no-brainer’ FTSE 100 shares I’d buy for 2024
Mark Tovey has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
